Skip to main content
ADXN
NASDAQ Life Sciences

Addex Therapeutics Seeks Shareholder Approval to Increase Capital for Future Funding

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$6.7
Mkt Cap
$6.698M
52W Low
$5.41
52W High
$12.05
52W Position info
24% above low
Off High info
44% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

ADXN sits 24% above its 52-week low of $5.41 on light trading volume (0.1× avg).

Summary

Addex Therapeutics announced its AGM agenda, including proposals to increase its capital band and conditional share capital, a necessary step for future equity financing given its "going concern" status.


Key Events · Financing and Capital Events · ADXN

  • AGM Convened

    Addex Therapeutics will hold its Annual General Meeting on June 29, 2026, to vote on several proposals.

  • Capital Increase Proposal

    Shareholders will vote on amendments to the Articles of Association to increase the company's capital band and conditional share capital.

  • Future Dilution Risk

    These proposals, if approved, authorize the company to issue additional shares, likely leading to significant dilution to raise necessary capital.

  • Addresses Going Concern

    This action directly follows the company's recent disclosure on May 15, 2026, of substantial doubt about its ability to continue as a going concern.


Analysis · ADXN · Life Sciences

Addex Therapeutics, which recently disclosed substantial doubt about its ability to continue as a going concern, is seeking shareholder approval at its upcoming Annual General Meeting to increase its capital band and conditional share capital. This move is a critical step to authorize future equity financing, which is necessary to address the company's precarious financial position and extend its operational runway. While it provides a path to survival, it also signals significant potential dilution for existing shareholders.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADXN was trading at $6.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $5.41 to $12.05. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADXN - Latest Insights

ADXN
Nov 11, 2026, 4:32 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.89
Real-time Price: $3.76 info
Change: +$0.870 (+30%) info
Market Cap: $5.184M info
ADXN
Sep 28, 2026, 7:06 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.73
Real-time Price: $3.76 info
Change: +$0.0282 (+0.76%) info
Market Cap: $5.184M info
ADXN
Sep 25, 2026, 6:05 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.70
Real-time Price: $3.76 info
Change: +$0.060 (+2%) info
Market Cap: $5.184M info
ADXN
Aug 26, 2026, 1:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.74
Real-time Price: $3.76 info
Change: +$0.0218 (+0.58%) info
Market Cap: $5.184M info
ADXN
Jun 30, 2026, 6:05 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $6.30
Real-time Price: $3.76 info
Change: -$2.54 (-40%) info
Market Cap: $5.184M info